SOURCE-LINKED STUDY SUMMARY
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
Abstract summarizedQuality not appraised
- What was studied
- Abstract-based design report for SURPASS-CVOT, a randomized, double-blind trial comparing weekly subcutaneous tirzepatide up to 15 mg with dulaglutide 1.5 mg.
- Who / model studied
- The trial randomized 13,299 adults across 640 sites in 30 countries; mean age was 64.1 years, with longstanding type 2 diabetes and established cardiovascular disease.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- No comparative cardiovascular results were available. The event-driven primary outcome was time to cardiovascular death, myocardial infarction or stroke, continuing until at least 1,615 events.
- Limitations & context
- This publication reports design and baseline characteristics while the trial was ongoing; it cannot establish tirzepatide’s cardiovascular safety or superiority.
Read summary source ↗ · Prepared 9/23/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/j.ahj.2023.09.007